Last edition
News about "breast cancer"
Laekna's LAE002 Breast Cancer Drug Application Accepted by China's NMPA
Laekna has advanced LAE002 toward potential commercialisation in China after the NMPA accepted its NDA for afuresertib in patients with advanced HR+/HER2- breast cancer.
Breast Cancer | 12/08/2026 | By News Bureau | 122
Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer
Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.
Breast Cancer | 10/08/2026 | By News Bureau | 111
Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer
Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.
Breast Cancer | 07/07/2026 | By News Bureau
Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer
Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.
Breast Cancer | 07/07/2026 | By News Bureau
Next-generation Nanomedicine can Silence Key Cancer Drivers: Research
Scientists in Pune have developed a next-generation precision nanomedicine that uses gene-silencing technology to target key cancer drivers and effectively inhibit breast tumor growth, highlighting a promising new approach for targeted breast cancer treatment and precision oncology.
Breast Cancer | 04/06/2026 | By News Bureau | 133
HeriCare-Breast01 study evaluates next-generation HER2 ADC against standard THInnovent BiologicsP regimen, following promising phase I/II efficacy and safety data presented at ASCO 2025.
Breast Cancer | 16/02/2026 | By News Bureau | 236
Innoblative Wins FDA IDE Approval for SIRA Device, Advancing Breast Cancer Surgery Innovation
Innoblative's SIRA device is a single-use, disposable applicator built for intraoperative ablation of the post-lumpectomy cavity during breast conserving surgery.
Breast Cancer | 11/04/2025 | By Abha | 618
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy